on ADOCIA (EPA:ADOC)
ADOCIA presents promising results for BioChaperone® Lispro
The biopharmaceutical company ADOCIA unveiled the complete results of the Phase 3 trial of THDB0206 (BioChaperone® Lispro) at the 86th Scientific Sessions of the American Diabetes Association in New Orleans. These data confirm the positive results announced in July 2025, highlighting non-inferiority in terms of HbA1c reduction compared to Humalog®, as well as an equivalent safety profile.
The study, conducted in China, demonstrates significant benefits, including improved long-term glycemic control and optimal management of postprandial blood glucose. These findings position BioChaperone® Lispro as a key innovation in the treatment of type 2 diabetes.
To discuss the results, ADOCIA is organizing a virtual event on June 16, 2026, bringing together experts in the field and the company's management.
R. H.
Copyright © 2026 FinanzWire, all reproduction and representation rights reserved.
Disclaimer: although drawn from the best sources, the information and analyzes disseminated by FinanzWire are provided for informational purposes only and in no way constitute an incentive to take a position on the financial markets.
Click here to consult the press release on which this article is based
See all ADOCIA news